InvestmentAug 6, 2026, 07:25 AM
Tarsus Pharmaceuticals Secures $125M Private Placement
AI Summary
Tarsus Pharmaceuticals, Inc. announced an oversubscribed private placement equity financing, expecting to raise approximately $125.0 million in gross proceeds. The financing involves the sale of common stock and pre-funded warrants to a syndicate of existing and new healthcare investors, including those from Alkeus Pharmaceuticals, which Tarsus is in the process of acquiring. The net proceeds are intended to support clinical development, commercial activities, and general corporate purposes, with the closing anticipated on August 7, 2026.
Key Highlights
- Secured approximately $125.0 million in gross proceeds from a private placement.
- Sold 2,098,519 shares of common stock at a purchase price of $56.00 per share.
- Sold pre-funded warrants to purchase 133,625 shares at $55.9999 per warrant.
- The private placement is expected to close on August 7, 2026.
- Net proceeds will fund clinical development, commercial activities, and general corporate purposes.
- Company and its directors/officers are subject to a 90-day lock-up agreement.
- Barclays Capital Inc. served as the lead placement agent for the financing.
Price Impact
More from TARS